Frederike Bensch
@fbensch.bsky.social
Pulmonologist with focus on thoracic oncology
Reposted by Frederike Bensch
ICYMI—Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
🔗 tinyurl.com/4fmmez9w #ASCO25
🔗 tinyurl.com/4fmmez9w #ASCO25
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
IRF progression-free survival and overall survival were longer in the lurbinectedin
plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit
with a higher incidence of adv...
tinyurl.com
June 18, 2025 at 3:04 PM
ICYMI—Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
🔗 tinyurl.com/4fmmez9w #ASCO25
🔗 tinyurl.com/4fmmez9w #ASCO25
Reposted by Frederike Bensch
This study found ALK, EGFR, BRAF & MET in 4% of squamous lung cancer cases. NGS matters—because finding the right mutation means access to the right treatment.
🔗 www.clinical-lung-cancer.com/article/S152...
#LCSM
🔗 www.clinical-lung-cancer.com/article/S152...
#LCSM
Brief Report: Real-World Clinical Utility of Next-Generation Sequencing of Circulating Tumor DNA for Patients with Advanced Lung Squamous Cell Carcinoma (SQUIN)
Next-generation sequencing (NGS) of tissue or plasma circulating tumor DNA (ctDNA)
can detect a wide spectrum of genomic alterations (GAs), guiding treatment decisions
in patients with non-small cell ...
www.clinical-lung-cancer.com
February 17, 2025 at 9:03 PM
This study found ALK, EGFR, BRAF & MET in 4% of squamous lung cancer cases. NGS matters—because finding the right mutation means access to the right treatment.
🔗 www.clinical-lung-cancer.com/article/S152...
#LCSM
🔗 www.clinical-lung-cancer.com/article/S152...
#LCSM
Ongoing search for effective 2nd line treatment in 🫁 cancer.
Sacituzumab Govitecan (TROP2 ADC) in ED SCLC in ph. 2 TROPiCS-03. ORR 41.9% (35% in platinum-res). PFS 4.4 mo, OS 13.6 mo. 74.4% >=gr.3 tox.
Despite advancements, need to do better (selection?).
pubmed.ncbi.nlm.nih.gov/39755168/
Sacituzumab Govitecan (TROP2 ADC) in ED SCLC in ph. 2 TROPiCS-03. ORR 41.9% (35% in platinum-res). PFS 4.4 mo, OS 13.6 mo. 74.4% >=gr.3 tox.
Despite advancements, need to do better (selection?).
pubmed.ncbi.nlm.nih.gov/39755168/
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03 - PubMed
SG demonstrated promising efficacy in the second-line treatment of ES-SCLC, irrespective of platinum sensitivity. Safety was manageable and consistent with that observed in other SG studies.
pubmed.ncbi.nlm.nih.gov
January 7, 2025 at 10:14 AM
Ongoing search for effective 2nd line treatment in 🫁 cancer.
Sacituzumab Govitecan (TROP2 ADC) in ED SCLC in ph. 2 TROPiCS-03. ORR 41.9% (35% in platinum-res). PFS 4.4 mo, OS 13.6 mo. 74.4% >=gr.3 tox.
Despite advancements, need to do better (selection?).
pubmed.ncbi.nlm.nih.gov/39755168/
Sacituzumab Govitecan (TROP2 ADC) in ED SCLC in ph. 2 TROPiCS-03. ORR 41.9% (35% in platinum-res). PFS 4.4 mo, OS 13.6 mo. 74.4% >=gr.3 tox.
Despite advancements, need to do better (selection?).
pubmed.ncbi.nlm.nih.gov/39755168/
Preparing local guidelines for 2025.
TNM9 for the classification of lung cancer.
journal.chestnet.org/article/S001...
TNM9 for the classification of lung cancer.
journal.chestnet.org/article/S001...
December 4, 2024 at 7:51 AM
Preparing local guidelines for 2025.
TNM9 for the classification of lung cancer.
journal.chestnet.org/article/S001...
TNM9 for the classification of lung cancer.
journal.chestnet.org/article/S001...